Navigation Links
BrainStorm CEO to Present at the Sachs Associates 2nd Annual Neuroscience Biopartnering and Investment Forum
Date:3/22/2017

HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 22, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will provide an update on new developments and a corporate overview at Sachs Associates 2nd Annual Neuroscience Biopartnering and Investment Forum, being held on March 27th at the New York Academy of Sciences.

Neuroscience Biopartnering and Investment Forum Presentation Details Date:      

Monday, March 27Time:             

2:20pm Eastern TimeLocation:       

New York Academy of Sciences, 7 World Trade Center

About the Annual Neuroscience BioPartnering & Investment ForumThe 2nd Annual Neuroscience BioPartnering & Investment Forum to take place on 27th of March at the New York Academy of Sciences. It will focus on key areas of neurodegenerative diseases and pain management with a mix of specialist panels and company presentations. The event is targeted at buy and sell side analysts from investment banks and funds and partnering executives from pharma. For more information, refer to http://www.sachsforum.com/2nbpi-about.html

About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel.  In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo.  For more information, visit the company's website at www.brainstorm-cell.com.

CONTACTSMedia:
Uri Yablonka
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188
uri@brainstorm-cell.com

Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979
mrice@lifesciadvisors.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-ceo-to-present-at-the-sachs-associates-2nd-annual-neuroscience-biopartnering-and-investment-forum-300427336.html


'/>"/>
SOURCE BrainStorm Cell Therapeutics Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. BrainStorm Cell Therapeutics Reports First Quarter 2016 Financial Results And Provides Corporate Update
2. BrainStorm Cell Therapeutics Announces Appointment of Dr. Revital Geffen-Aricha as Vice President of Research & Development
3. BrainStorm Hosting Conference Call to Update Shareholders on Important Developments
4. BrainStorm Awarded Additional $735,000 Non-Dilutive Grant for 2015 from Israels Office of the Chief Scientist
5. BrainStorm Cell Therapeutics Reports Third Quarter 2015 Financial Results And Provides Corporate Update
6. BrainStorm Cell Therapeutics to Present at 2015 Stem Cell Meeting on the Mesa
7. BrainStorm Cell Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update
8. BrainStorm Cell Therapeutics to Report Second Quarter 2015 Financial Results on Thursday, August 13
9. BrainStorm Cell Therapeutics to Report First Quarter 2015 Financial Results on Thursday, May 14
10. BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israels Chief Scientist Office
11. BrainStorm Cell Therapeutics to Report Third Quarter 2014 Financial Results on Thursday, November 13
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/9/2018)... ... August 09, 2018 , ... MedEvolve, Inc. ... engagement and analytics software and services for physician practices, announced today the company’s ... history. After back-to-back record quarters in Q2 and Q3 last year, the company ...
(Date:8/1/2018)... ... August 01, 2018 , ... ... announces research results on the significant impact of a proprietary biofield energy ... , The preclinical research assessed biomarkers for systemic and organ-specific inflammation, as ...
(Date:7/26/2018)... ... July 26, 2018 , ... Ariadne Afaganis, an evidence-based ... energy treated nutraceutical to improve anti-inflammatory and immune function responses. , Biomarkers for ... preclinical research, were significantly reduced. Results are as follows:, ...
(Date:7/25/2018)... , ... July 25, 2018 , ... ... for managing clinical trial patient and supplies data through its flagship IXRS® ... on IRT: Best Practices.” , This podcast features both Almac thought leaders and ...
Breaking Biology Technology:
(Date:7/26/2018)... ... July 25, 2018 , ... Boston ... executives on September 4, 2018 at The Hilton Boston Back Bay Hotel. This ... business development experiences and dissect the most relevant deals in biotech. , George ...
(Date:7/26/2018)... ... July 26, 2018 , ... The Conference Forum has confirmed the agenda for ... 24, 2018 at the Marriott Copley Place in Boston, MA. , Daniel Karlin, MD, ... as program chair to lead the discussion on how and when to implement mobile/digital ...
(Date:7/25/2018)... ... ... pioneering Duchenne muscular dystrophy clinical trial is now recruiting patients at two sites in ... the need to enroll patients. , “There is no cure for Duchenne, and ... a clinical trial,” said Catherine Jayasuriya, the founder and executive director of Coalition Duchenne, ...
Breaking Biology News(10 mins):